Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Cheeseman MD"'
Autor:
Cheeseman, MD, Westwood, IM, Barbeau, O, Rowlands, M, Dobson, S, Jones, AM, Jeganathan, F, Burke, R, Kadi, N, Workman, P, Collins, I, van Montfort, RL, Jones, K
HSP70 is a molecular chaperone and a key component of the heat-shock response. Because of its proposed importance in oncology, this protein has become a popular target for drug discovery, efforts which have as yet brought little success. This study d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______128::0133f6371bc3d56bc5e234214a979624
https://e-space.mmu.ac.uk/613362/
https://e-space.mmu.ac.uk/613362/
Autor:
Liu M; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Mirza A; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., McAndrew PC; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Thapaliya A; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Pierrat OA; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Stubbs M; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Hahner T; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Chessum NEA; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Innocenti P; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Caldwell J; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Cheeseman MD; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Bellenie BR; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., van Montfort RLM; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K., Newton GK; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Burke R; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Collins I; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Hoelder S; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2023 Aug 10; Vol. 66 (15), pp. 10617-10627. Date of Electronic Publication: 2023 Jul 19.
Autor:
Pasqua AE; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Sharp SY; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Chessum NEA; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Hayes A; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Pellegrino L; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Tucker MJ; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Miah A; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Wilding B; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Evans LE; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Rye CS; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Mok NY; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Liu M; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Henley AT; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Gowan S; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., De Billy E; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Te Poele R; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Powers M; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Eccles SA; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Clarke PA; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Raynaud FI; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Workman P; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Jones K; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Cheeseman MD; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2023 Apr 27; Vol. 66 (8), pp. 5907-5936. Date of Electronic Publication: 2023 Apr 05.
Autor:
Wilding B; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Pasqua AE; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., E A Chessum N; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Pierrat OA; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Hahner T; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Tomlin K; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Shehu E; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Burke R; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Richards GM; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Whitton B; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Arwert EN; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Thapaliya A; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK; Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, UK., Salimraj R; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK; Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, UK., van Montfort R; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK; Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, UK., Skawinska A; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Hayes A; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Raynaud F; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Chopra R; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Jones K; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Newton G; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK., Cheeseman MD; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK. Electronic address: Matthew.Cheeseman@icr.ac.uk.
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2021 Jun 15; Vol. 42, pp. 128050. Date of Electronic Publication: 2021 Apr 20.
Autor:
Pettinger J; Cancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SW7 3RP , United Kingdom., Carter M; Cancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SW7 3RP , United Kingdom., Jones K; Cancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SW7 3RP , United Kingdom., Cheeseman MD; Cancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SW7 3RP , United Kingdom.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2019 Dec 26; Vol. 62 (24), pp. 11383-11398. Date of Electronic Publication: 2019 Dec 06.
Autor:
Meyers J; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Chessum NEA; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Ali S; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Mok NY; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Wilding B; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Pasqua AE; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Rowlands M; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Tucker MJ; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Evans LE; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Rye CS; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., O'Fee L; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Le Bihan YV; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Burke R; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Carter M; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Workman P; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Blagg J; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Brown N; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., van Montfort RLM; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Jones K; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Cheeseman MD; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom.
Publikováno v:
ACS medicinal chemistry letters [ACS Med Chem Lett] 2018 Nov 16; Vol. 9 (12), pp. 1199-1204. Date of Electronic Publication: 2018 Nov 16 (Print Publication: 2018).
Autor:
Chessum NEA; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Sharp SY; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Caldwell JJ; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Pasqua AE; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Wilding B; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Colombano G; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Collins I; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Ozer B; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Richards M; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Rowlands M; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Stubbs M; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Burke R; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., McAndrew PC; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Clarke PA; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Workman P; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Cheeseman MD; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Jones K; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2018 Feb 08; Vol. 61 (3), pp. 918-933. Date of Electronic Publication: 2018 Jan 05.
Autor:
Pettinger J; Cancer Research, UK, Cancer Therapeutics Unit, The Institute of Cancer Research, London, SW7 3RP, UK., Jones K; Cancer Research, UK, Cancer Therapeutics Unit, The Institute of Cancer Research, London, SW7 3RP, UK., Cheeseman MD; Cancer Research, UK, Cancer Therapeutics Unit, The Institute of Cancer Research, London, SW7 3RP, UK.
Publikováno v:
Angewandte Chemie (International ed. in English) [Angew Chem Int Ed Engl] 2017 Nov 27; Vol. 56 (48), pp. 15200-15209. Date of Electronic Publication: 2017 Oct 27.
Autor:
Evans LE; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SW7 3RP, UK. matthew.cheeseman@icr.ac.uk., Jones K; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SW7 3RP, UK. matthew.cheeseman@icr.ac.uk., Cheeseman MD; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SW7 3RP, UK. matthew.cheeseman@icr.ac.uk.
Publikováno v:
Chemical communications (Cambridge, England) [Chem Commun (Camb)] 2017 May 04; Vol. 53 (37), pp. 5167-5170.
Autor:
Pettinger J; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SW7 3RP, UK., Le Bihan YV; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SW7 3RP, UK.; Division of Structural Biology, The Institute of Cancer Research, London, SW7 3RP, UK., Widya M; Proteomics Core Facility, The Institute of Cancer Research, London, SW7 3RP, UK., van Montfort RL; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SW7 3RP, UK.; Division of Structural Biology, The Institute of Cancer Research, London, SW7 3RP, UK., Jones K; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SW7 3RP, UK., Cheeseman MD; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SW7 3RP, UK.
Publikováno v:
Angewandte Chemie (International ed. in English) [Angew Chem Int Ed Engl] 2017 Mar 20; Vol. 56 (13), pp. 3536-3540. Date of Electronic Publication: 2017 Feb 22.